Exploring the DaBlaCa-13 study, chemoresection with dose-dense mitomycin C in patients with recurrent non-muscle-invasive bladder cancer - European Medical Journal

Continue

A podcast exploring the DaBlaCa-13 study, chemoresection with dose-dense mitomycin C (MMC) in patients with recurrent non-muscle-invasive bladder cancer (intermediate-risk)

Urology

The EMJ Podcast | Bonus Episode

Tune in for a fascinating discussion with Jørgen Bjerggaard Jensen, Department of Urology, Aarhus University, Denmark, as he explores recent breakthroughs in non-muscle-invasive bladder cancer (NMIBC) management through mitomycin C (MMC) chemoresection.

Spotify | Apple | Amazon Music | Download MP3 (17:30 mins)

 

Jensen addresses the critical need to advance NMIBC management, underscoring its unique status as a disease of field cancerisation. Delving into the study’s main findings, Jensen discusses the efficacy of MMC chemoresection and the potential effectiveness in both low-grade and high-grade Ta tumours. Safety and tolerability aspects are also examined, highlighting the promise this intervention holds for patients and urologists alike.

This content was funded by medac GmbH.

References

1. Lindgren MS et al. DaBlaCa-13 study: oncological outcome of short-term, intensive chemoresection with mitomycin in nonmuscle invasive bladder cancer: primary outcome of a randomized controlled trial. J Clin Oncol. 2023;41(2):206-11.
2. Oresta B et al. Mitochondrial metabolic reprogramming controls the induction of immunogenic cell death and efficacy of chemotherapy in bladder cancer. Sci Transl Med. 2021;13(575):eaba6110.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.